Please Wait.....
Report
Novartis AG (NOVN:SWX) Strategic SWOT Analysis and Financial Insights - A 360? Review of Opportunities, Challenges and Risk, Corporate and ESG Strategies, Competitive Intelligence, Financial and Operational KPI?s, and Recent Trends
Company Report I 2025-02-27 I 116 Pages I Quaintel Research
Report Summary
Novartis AG (NOVN:SWX) Strategic SWOT Analysis and Financial Insights - A 360 Review of Opportunities, Challenges and Risk, Corporate and ESG Strategies, Competitive Intelligence, Financial and Operational KPIs, and Recent Trends Report is a comprehensive and easily accessible overview of Novartis AG's business operations. It provides a detailed analysis of the company's financial and strategic standing, as well as its position in the industry compared to competitors. The report includes several key features to facilitate decision-making and provide insights into the company's performance.
The report begins with in-depth information about Novartis AG, including key insights, business segments, key executives, locations, products and services, historical events, corporate strategy, and management discussions. This section provides a solid foundation for understanding the company's key attributes.
Next, the report assesses Novartis AG's strategic standing through various analyses. The ESG spotlight evaluates the company's environmental, social, and governance performance, providing insights into its sustainability efforts and ethical practices. The SWOT analysis examines the company's internal strengths and weaknesses, as well as external opportunities and threats. Additionally, By integrating these strategic analyses, the report offers a comprehensive understanding of Novartis AG's overall strategic standing and supports informed decision-making and strategic planning.
The report also covers Novartis AG's financial analysis basis of latest income statement, balance sheet, and cash flow statement. Key financial ratios related to profitability, asset turnover, credit, market, and long-term solvency are outlined, providing guidance for investment decisions. Furthermore, the report compares Novartis AG's financial parameters with those of its competitors, offering a unique analysis of the competitive landscape. This information helps manage the business environment and improve sales activities by gaining insight into competitors' operations.
Finally, the report includes recent news and deal activities undertaken by Novartis AG, enhancing awareness of the company's business trends, growth perspectives, and more.
Key Highlights
Novartis AG operates as a healthcare company that researches, develops, manufactures, and markets healthcare products. Novartis AG operates in the healthcare industry and is segmented into innovative medicines and sandoz divisions. The innovative medicines division focuses on prescription medicines in therapeutic areas like cardiovascular, neuroscience, immunology and oncology among others. The sandoz division offers generic medicines. Novartis AG offers prescription medicines and focuses on therapeutic areas such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, ophthalmology and hematology. It has a collaboration with Alnylam Pharmaceuticals to develop inclisiran to reduce LDL cholesterol. Novartis products reach nearly 800 million people globally. The company is finding innovative ways to expand access to its latest treatments. Founded in 1996, the company is headquartered in Basel, Basel-Stadt, Switzerland.
Novartis AG in the News:-
- 30-Dec-2024 - Novartis intrathecal onasemnogene abeparvovec Phase III study meets primary endpoint in children and young adults with SMA
- 10-Dec-2024 - Longer-term Novartis Kisqali NATALEE data show durable reduction in distant recurrence in broad population of patients with early breast cancer
- 06-Dec-2024 - New Phase IIIB data shows Novartis Fabhalta improved hemoglobin levels in adult patients with paroxysmal nocturnal hemoglobinuria who switched from anti-C5 therapy
- 02-Dec-2024 - Novartis bolsters Neuroscience pipeline with in-licensing of PTC518 for Huntingtons disease
- 27-Nov-2024 - Novartis Kisqali receives European Commission approval in a broad population of patients with HR+/HER2- early breast cancer at high risk of recurrence
Scope
Tactical Analysis:- Various strategic frameworks to gain insights into a company's competitive position and operational environment. These analytical tools assist in identifying competitive advantages, potential risks, and areas for improvement and efficiency, enabling companies to make informed tactical decisions.
Business Strategy:- Contributes to shaping the company's overall direction, goals, and decision-making processes, ensuring long-term success and alignment with stakeholder expectations.
Financial Position:- Provide valuable information on the financial performance and investor sentiment surrounding the company. Indicating the level of confidence and expectations in the company's future prospects. These components collectively contribute to understanding the financial health and market perception of the company.
Company Fundamentals:- These fundamentals offer valuable insights into the company's history, operations, leadership, and geographical presence, aiding in a comprehensive understanding of the organization.
Competitive Landscape:- An identification of the company's main competitors, providing insights into the competitive landscape it operates in.
Reasons to Buy
Comprehensive Understanding of the Novartis AG's internal and external factors through SWOT analysis, Financial Analysis, and Competitors Benchmarking.
Strive Strategic Decision Making with various analyses and identifying potential customers and suppliers.
Mitigate Risk with help of thorough analysis of internal and external factors. Furthermore, develop strategies and contingency plans to address these challenges and minimize their impact on business operations.
Competitive Benchmarking will help to gain a competitive advantage by understanding industry trends, customer preferences, and best practices.
Financial Performance Evaluation provides crucial insights into key financial ratios and trends, supporting better financial decision-making and resource allocation.
Valuable insights from the report enable investors and partners to make informed decisions regarding potential Collaborations, Investments, or Partnerships with the company.
Additionally, available deep-dive analysis on the company Novartis AG:
Novartis AG PESTLE Analysis
Novartis AG Porter's Five Forces Analysis
Novartis AG VRIO Analysis
Novartis AG BCG Analysis
Novartis AG Segmentation, Targeting and Positioning (STP) Analysis
Novartis AG Ansoff Matrix Analysis
Table of Contents
COMPANY EXECUTIVE SUMMARY 1
Table of Contents 2
Tables 6
Charts 7
Novartis AG - Key Company Facts 8
Novartis AG - Company Description 9
Novartis AG - Top Executives 10
Novartis AG- Top Executives Biographies 11
Novartis AG- Head Office & Locations 15
Head Office - Country 15
Key Subsidiaries 16
Key Joint Ventures 17
Novartis AG - Products and Services 18
Products 18
Services 19
Novartis AG - Historic Events 20
Novartis AG - Company's Mission and Vision 21
Mission 21
Vision 21
Novartis AG - Corporate Strategy 22
Novartis AG - Business Description 28
Cardiovascular, renal and metabolic 29
Immunology 30
Neuroscience 31
Oncology 31
Established brands 32
Novartis AG - ESG Spotlight 34
Environment 34
Social 35
Corporate Governance 36
Novartis AG - SWOT Analysis 37
Overview 37
Strengths 39
Weaknesses 42
Opportunities 43
Threats 45
Novartis AG - Financial Deep Dive 46
Share Price Trend - Feb-2024 to Feb-2025 (Average Share Closing Price) 46
Profit and Loss Statement 48
Summary of Profit and Loss Statement 48
Balance Sheet 50
Summary of Balance Sheet 50
Cash Flow Statement 52
Summary of Cash Flow Statement 52
Key Financial Ratio Analysis 54
Novartis AG - Ratio Charts 55
Activity Ratio Charts 55
Growth Ratios Charts 56
Leverage Ratio Charts 57
Liquidity Ratio Charts 58
Profitability Ratio Charts 59
Competing Players 60
Snapshot of Competing Players 61
AbbVie Inc 61
Key Company Facts 61
Company Description 61
Snapshot of Competing Players 62
Roche Holding AG 62
Key Company Facts 62
Company Description 62
Snapshot of Competing Players 63
Johnson & Johnson 63
Key Company Facts 63
Company Description 63
Snapshot of Competing Players 64
Pfizer Inc. 64
Key Company Facts 64
Company Description 64
Snapshot of Competing Players 65
Merck & Co., Inc. 65
Key Company Facts 65
Company Description 65
Novartis AG - In the News 66
30-Dec-2024 -Novartis intrathecal onasemnogene abeparvovec Phase III study meets primary endpoint in children and young adults with SMA 66
10-Dec-2024 -Longer-term Novartis Kisqali NATALEE data show durable reduction in distant recurrence in broad population of patients with early breast cancer 68
06-Dec-2024 -New Phase IIIB data shows Novartis Fabhalta improved hemoglobin levels in adult patients with paroxysmal nocturnal hemoglobinuria who switched from anti-C5 therapy 69
02-Dec-2024 -Novartis bolsters Neuroscience pipeline with in-licensing of PTC518 for Huntington's disease 70
27-Nov-2024 -Novartis Kisqali receives European Commission approval in a broad population of patients with HR+/HER2- early breast cancer at high risk of recurrence 70
15-May-2024 -Novartis highlights pioneering innovation in CML with data from Scemblix Phase III ASC4FIRST study in newly diagnosed patients at ASCO and EHA 72
10-May-2024 -Novartis receives FDA Breakthrough Therapy designation for Scemblix in 1L CML 72
24-Apr-2024 -Novartis and Medicines for Malaria Venture announce positive efficacy and safety data for a novel treatment for babies <5 kg with malaria 74
23-Apr-2024 -Novartis radioligand therapy Lutathera FDA approved as first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumors 76
17-Apr-2024 -Novartis Kesimpta six-year efficacy data show substantial benefits in recently diagnosed treatment- naive people with relapsing multiple sclerosis 78
15-Apr-2024 -New Novartis Fabhalta (iptacopan) data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for patients with IgA nephropathy (IgAN) 81
09-Apr-2024 -Novartis implements manufacturing adjustments for ribociclib to ensure alignment with latest regulatory standards in eBC by end of Q2 83
06-Apr-2024 -New Novartis data show early addition of twice-yearly* Leqvio (inclisiran) following maximally tolerated statin therapy significantly reduces LDL-C in ASCVD patients in real-world setting 84
22-Mar-2024 -Novartis Fabhalta (iptacopan) receives positive CHMP opinion as first oral monotherapy for adult patients with paroxysmal nocturnal hemoglobinuria (PNH) 86
04-Mar-2024 -Novartis presents new data on safety and efficacy of Zolgensma, including maintained and improved motor milestones in older and heavier children with SMA 89
Novartis AG - Key Deals 92
11-Feb-2025 - Novartis bolsters late-stage cardiovascular pipeline with agreement to acquire Anthos Therapeutics for USD 925 million upfront 93
16-May-2024 - Novartis meets all tender offer conditions to acquire MorphoSys AG for EUR 68 per share in cash 95
02-May-2024 - Novartis enters agreement to acquire Mariana Oncology, strengthening radioligand therapy pipeline 97
05-Feb-2024 - Novartis to strengthen oncology pipeline with agreement to acquire MorphoSys AG for EUR 68 per share or an aggregate of EUR 2.7bn in cash 98
19-Sep-2023 - Novartis statement on collaboration and license agreement for tislelizumab with BeiGene, Ltd. 102
28-Aug-2023 - Sandoz completes acquisition of leading antifungal agent Mycamine from Astellas, reinforcing leading global anti-infectives portfolio 102
11-Aug-2023 - Novartis completes acquisition of Chinook Therapeutics 103
17-Jul-2023 - Novartis builds on neuroscience pipeline and xRNA platform capabilities with acquisition of DTx Pharma 104
30-Jun-2023 - Novartis signs agreement to divest 'front of eye' ophthalmology assets in line with focused strategy 105
12-Jun-2023 - Novartis bolsters innovative medicines strategy and renal pipeline with agreement to acquire Chinook Therapeutics for USD 3.2bn upfront (USD 40 / share) 105
09-May-2023 - Sandoz strengthens pipeline expansion through partnership to develop and manufacture multiple biosimilars 108
Appendix 109
Definitions 109
SWOT Analysis 109
PESTLE Analysis 109
Value Chain Analysis 109
ESG Spotlight 109
Financial Deep Dive 109
Financial Ratios - 110
Activity Ratios 110
Growth Ratios 111
Leverage Ratios 112
Liquidity Ratios 113
Market Ratios 114
Profitability Ratios 114
Research Methodology 115
Disclaimer 116
Contact Us 116
Tables
Table 1: Novartis AG - Company Facts
Table 2: Novartis AG - Digital Presence
Table 3: Novartis AG - Top Executives
Table 4: Novartis AG - Top Executives Biographies
Table 5: Novartis AG - Subsidiaries
Table 6: Novartis AG - Key Joint Ventures
Table 7: Novartis AG - Products
Table 8: Novartis AG - Services
Table 9: Novartis AG - Historic Events
Table 10: Novartis AG - Share Price Trend - Feb-2024 to Feb-2025
Table 11: Novartis AG - Ratio Analysis - 2021-2024
Table 12: Novartis AG - Competing Players
Table 13: Competing Players - AbbVie Inc - Key Company Facts
Table 14: Competing Players - Roche Holding AG - Key Company Facts
Table 15: Competing Players - Johnson & Johnson - Key Company Facts
Table 16: Competing Players - Pfizer Inc. - Key Company Facts
Table 17: Competing Players - Merck & Co., Inc. - Key Company Facts
Charts
Figure 1: Novartis AG- SWOT Analysis
Figure 2: Novartis AG - Average Share Price Trend - Feb-2024 to Feb-2025
Figure 3: Novartis AG - Profit and Loss Statement - 2021-2024
Figure 4: Novartis AG - Balance Sheet - 2021-2024
Figure 5: Novartis AG - Cash Flow Statement 2021-2024
Figure 6: Novartis AG - Activity Ratio Charts
Figure 7: Novartis AG - Growth Ratio Charts (Value %)
Figure 8: Novartis AG - Leverage Ratio Charts
Figure 9: Novartis AG - Liquidity Ratio Charts
Figure 10: Novartis AG - Profitability Ratio Charts (Value %)
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security